Special Issue

Urinary Tract Infections and Antibiotic Intervention

Message from the Guest Editors

Urinary tract infections are one of the most common infectious diseases in human beings. Despite significant progress in the invention of more powerful and wider spectrum antibiotics, mortality and morbidity of UTIs in patients with UTI have not decreased significantly. This is partly because of overuse of antibiotics resulting in more resistant strains and because of a lack of complete understanding of microbial flora of the urinary tract. The protective role of the urinary microbiome and its changes alongside patients' unusual conditions, including external catheters, internal stents, consumption of antibiotics, and underlying diseases, has become an important research topic not only in UTIs, but also in other disease conditions, such as interstitial cystitis, prostatitis, and pelvic pain. This Special Issue seeks manuscripts that increase our understanding of the urinary microbiome and of the relationship of the microbiome with different disease conditions, clarifying the indication for treatment of UTIs with different levels of symptoms, overuse of antibiotics and its detrimental effects, superbugs, and antibiotic stewardship in UTIs.

Guest Editors

Dr. Maiid Mirzazadeh

Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Dr. John W. Sanders

Wake Forest School of Medicine, Winston-Salem, NC 27101, USA

Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/137700

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

